The FDA Approved a Once-Daily Parkinson's Pill Called Juvmo
The FDA approved Juvmo, a once-daily D1/D5 pill for Parkinson's. In TEMPO-3 it added 1.7 hours of on-time versus 0.6 on placebo. It is not a cure.
Tavapadon is the first D1/D5 agonist cleared for the disease. It is not a replacement for levodopa.
The US Food and Drug Administration approved tavapadon, brand name Juvmo, for adults with Parkinson's disease. Drugs.com records the first approval as 25 September 2026. AbbVie and MedPage Today announced it on 28 September. AbbVie expects the tablets in US pharmacies in October 2026, which is why it is in today's file rather than last month's.
Juvmo is a once-daily oral selective D1/D5 partial agonist. Other dopamine agonists in common use mainly hit D2/D3 receptors. It can be taken with or without levodopa. Tablets are 5, 10 and 15 mg, with a titration pack of 0.25 and 1 mg. The University of Virginia says the pill rests on work by pharmacology professor Richard B. Mailman, and that earlier drugs in the class had to be injected.
The phase 3 TEMPO programme tested it as monotherapy in early disease (TEMPO-1 and TEMPO-2) and as an add-on for people with motor fluctuations (TEMPO-3). TEMPO-3 enrolled adults on a stable levodopa dose. At week 26, daily "on" time without troublesome dyskinesia increased by 1.7 hours with tavapadon versus 0.6 hours with placebo. Daily "off" time fell by 1.9 hours versus 0.9. MedPage Today notes that the drug may also lead to psychotic-like behaviour and hallucinations, a risk that can rise with strong CYP3A inhibitors. There is no claim here that it stops the disease.
UVA reported on 13 October that 93 percent of trial participants had not increased their levodopa dose after 85 weeks, and 94 percent of those with early disease had not started levodopa. That is an open-label extension signal, not a head-to-head cure claim. This is a different medicine from the stem-cell Parkinson's work this site has already covered.
Key Facts
- FDA approval: 25 September 2026 (Drugs.com); announced 28 September (AbbVie / MedPage Today)
- US availability expected: October 2026
- TEMPO-3, week 26: +1.7 hours on-time without troublesome dyskinesia vs +0.6 on placebo; off-time −1.9 vs −0.9 hours
- Once daily; first approved D1/D5 agonist for Parkinson's
- Hallucinations are a labelled risk
- Sources: Drugs.com, MedPage Today, Pharmacy Times, UVA Health
Why This Matters
People with Parkinson's spend the day negotiating "on" and "off." An extra hour and a half of usable on-time, against a placebo that managed 36 minutes, is a concrete change. It is still a symptomatic drug with psychiatric side effects.
What We Don't Know Yet
We do not have a full adverse-event table in front of us, a price, or a European decision. The 85-week levodopa figures are from an extension, not from the blinded 26-week comparison. Do not tell anyone to switch treatment on the basis of this piece.